Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN FRANCISCO and GENEVA, July 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, June 30, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, June 15, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, June 10, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for Multiple Sclerosis and Alzheimer's disease,...
-
SAN FRANCISCO and GENEVA, June 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic...
-
SAN FRANCISCO and GENEVA, May 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
SAN FRANCISCO and GENEVA, May 22, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for...
-
- Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch - - Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 - SAN FRANCISCO and...